Clinical Trials Using Lenvatinib Mesylate
Clinical trials are research studies that involve people. The clinical trials on this list are studying Lenvatinib Mesylate. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Lenvatinib and Pembrolizumab for the Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma or Other Salivary Gland Cancers
This phase II trial studies how well lenvatinib and pembrolizumab work in treating patients with adenoid cystic carcinoma or other salivary gland cancers that have come back (recurrent) or have spread to other places in the body (metastatic). Lenvatinib works by blocking receptor tyrosine kinases, proteins that help cells grow and develop blood vessels. Blocking these proteins may slow the growth of cancer cells and cut off the blood supply that feeds them. Pembrolizumab blocks a protein, PD-1, that acts as a “brake” on the immune system. Blocking this protein is like releasing the brakes; it frees the immune system to target and kill cancer cells. Giving lenvatinib and pembrolizumab may work better in slowing and stopping the growth of adenoid cystic carcinoma or other salivary gland cancers compared to lenvatinib or pembrolizumab alone.
Location: 8 locations
Lenvatinib Mesylate and Cetuximab in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma or Cutaneous Squamous Cell Carcinoma
This phase I / Ib trial studies the best dose and side effects of lenvatinib mesylate and cetuximab in treating patients with head and neck squamous cell carcinoma or cutaneous squamous cell carcinoma that has come back (recurrent) or spread to other places in the body (metastatic). Lenvatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, may interfere with the ability of tumor cells to grow and spread. Giving lenvatinib mesylate and cetuximab may work better in treating patients with head and neck squamous cell carcinoma or cutaneous squamous cell carcinoma.
Location: 7 locations
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365 / KEYNOTE-365)
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in patients with metastatic castrate resistant prostate cancer (mCRPC). There will be nine cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab + docetaxel + prednisone, Cohort C will receive pembrolizumab + enzalutamide, Cohort D will receive pembrolizumab + abiraterone + prednisone Cohort E will receive pembrolizumab+lenvatinib, Cohort F will receive pembrolizumab+lenvatinib, Cohort G will receive vibostolimab (+) pembrolizumab coformulation (MK-7684A), Cohort H will receive vibostolimab (+) pembrolizumab coformulation, and Cohort I will receive pembrolizumab+carboplatin+etoposide in Arm 1 and carboplatin+etoposide in Arm 2. Outcome measures will be assessed individually for each cohort.
Location: 7 locations
A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
This Is a Multicenter, Randomized, Open-Label, Parallel-Group, Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide Versus Ifosfamide and Etoposide in Children, Adolescents, and Young Adults with Relapsed or Refractory Osteosarcoma.
Location: 8 locations
A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013 / E7080)
The main purpose of this study is to evaluate the antitumor activity and safety of Lenvatinib (MK-7902 / E7080) in children, adolescents, and young adults with relapsed or refractory solid malignancies after administration. Participants will be enrolled into initial tumor-specific cohorts which will be expanded based on observed response.
Location: 2 locations
Lenvatinib and Pembrolizumab before Surgery for the Treatment of Locally Advanced Non-Metastatic Kidney Cancer
This phase II trial studies how well lenvatinib and pembrolizumab before surgery work in treating patients with kidney cancer that has spread from its original site of growth to nearby tissues or lymph nodes (locally advanced) but has not spread to other places in the body (non-metastatic). Lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving lenvatinib and pembrolizumab before surgery may kill more tumor cells.
Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia
Study of MK-4280 as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib AND MK-4280A as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)
This is a safety and pharmacokinetics study of MK-4280 as monotherapy and in combination with pembrolizumab (MK-3475) AND MK-4280A as monotherapy in adults with metastatic solid tumors for which there is no available therapy which may convey clinical benefit. Part A of this study is a dose escalation design in which participants receive MK-4280 as monotherapy or MK-4280 in combination with pembrolizumab. Part B is a dose confirmation design to estimate the recommended Phase 2 dose (RP2D), as determined by dose-limiting toxicity, for MK-4280 in combination with pembrolizumab or pembrolizumab and lenvatinib in participants with advanced solid tumors. Part B will also assess the efficacy of MK-4280 as monotherapy; MK-4280 in combination with pembrolizumab with and without chemotherapy; MK-4280 in combination with pembrolizumab and lenvatinib; and MK-4280A as monotherapy in expansion cohorts.
Location: 4 locations